ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.070

-8.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

bobbseytwins2001

To: jargonweary who wrote (1101)	7/16/2025 8:10:47 PM
From: waitwatchwander	1 Recommendation of 1223

Anktiva is an expensive life extending treatment. There is only a certain class of people who can afford and be helped by it. Getting the word out in whatever way one can is required for this drug to be successful. It is sure to be a slow and steady climb to cash flow positive and profitability or sale to a greater enabler. PSS does understand this part of the challenge. Success to him is helping all that he can muster into the Anktiva camp. JMO

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next